Drug intelligence / Profile preview

EA0010

Development stage: Unknown
Lead developer: Shanghai Jiao Tong University School of Medicine
Modality: AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration: Unknown (likely Local Administration Such As Intralabyrinthine Or Intracochlear Injection Based On Typical Routes For Inner Ear Gene Therapies; Specific Route Not Stated In Available Data)[1]

Overview

EA0010 is an AAV-based gene therapy developed by The Ninth People's Hospital of Shanghai Jiaotong University Medical College. It is being investigated primarily for the treatment of hearing loss, with potential applications in other nervous system and otorhinolaryngologic diseases. As an adeno-associated virus (AAV) vector gene therapy, it aims to deliver genetic material to target cells in order to restore or modify function related to disease pathology. The drug is currently in early phase 1 clinical development[1].

Beyond the preview

Go deeper on EA0010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EA0010.

Explore the full profile